Novavax (NVAX)
(Delayed Data from NSDQ)
$12.91 USD
+0.39 (3.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $12.92 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NVAX 12.91 +0.39(3.12%)
Will NVAX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVAX
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
Company News for Sep 3, 2024
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
Other News for NVAX
Shah Capital Management Increases Stake in Emeren Group Ltd
$1000 Invested In Novavax 5 Years Ago Would Be Worth This Much Today
Notable Tuesday Option Activity: NVAX, ANET, PLL
DeSantis Administration Cautions Against Pfizer, Moderna mRNA Covid Vaccines for Vulnerable Individuals, Cites Concerns Related To Rare Heart Conditions
Contradicting experts, Fla. health chief advises seniors to avoid mRNA COVID-19 boosters